1
|
Rebić N, Park JY, Garg R, Ellis U, Kelly A, Davidson E, De Vera MA. Rapid Review of Medication Taking (Adherence) Among Patients With Rheumatic Diseases During the COVID-19 Pandemic. Arthritis Care Res (Hoboken) 2022; 74:1961-1969. [PMID: 34219400 PMCID: PMC8426729 DOI: 10.1002/acr.24744] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 06/15/2021] [Accepted: 07/01/2021] [Indexed: 02/05/2023]
Abstract
OBJECTIVE We aimed to identify, appraise, synthesize, and contextualize rapidly emerging reports on medication taking (adherence) among patients with rheumatic diseases during the COVID-19 pandemic. METHODS We searched MEDLINE, EMBASE, and CINAHL for peer-reviewed communications, letters, and articles published during the COVID-19 pandemic evaluating medication taking among individuals with rheumatic diseases. We appraised assessment and reporting of medication adherence according to established definitions of 3 distinct problems of medication taking (i.e., noninitiation, poor implementation, and discontinuation) and pooled findings using random-effects models. RESULTS We included 31 peer-reviewed studies in our synthesis from various jurisdictions, of which 25 described medication taking among rheumatology patients and 6 described medication prescribing among rheumatology providers. The pooled prevalence of overall medication nonadherence was 14.8% (95% confidence interval [95% CI] 12.3-17.2) and that of medication discontinuation (i.e., stopping of prescriptions) and poor implementation (i.e., not taking medication at the dose/frequency prescribed) as 9.5% (95% CI 5.1-14.0) and 9.6% (95% CI 6.2-13.0), respectively. Noninitiation (i.e., not starting/not filling new prescriptions) was not addressed. CONCLUSION Medication taking among individuals with rheumatic diseases during the COVID-19 pandemic varies globally. Unclear reporting and extensive variation in research methods between studies create barriers to research replication, comparison, and generalization to specific patient populations. Future research in this area should use consistent and transparent approaches to defining and measuring medication taking problems to ensure that findings appropriately describe the epidemiology of medication adherence and have the potential to identify modifiable targets for improving patient care.
Collapse
Affiliation(s)
- Nevena Rebić
- University of British Columbia and Collaboration for Outcomes Research and Evaluation, Vancouver, and Arthritis Research CanadaRichmondBritish ColumbiaCanada
| | - Jamie Y. Park
- University of British Columbia and Collaboration for Outcomes Research and EvaluationVancouverBritish ColumbiaCanada
| | - Ria Garg
- University of British Columbia and Collaboration for Outcomes Research and EvaluationVancouverBritish ColumbiaCanada
| | - Ursula Ellis
- University of British ColumbiaVancouverBritish ColumbiaCanada
| | - Ayano Kelly
- Australian National University and Canberra Rheumatology, Canberra, ACT, and The Children's Hospital at WestmeadSydneyNew South WalesAustralia
| | | | - Mary A. De Vera
- University of British Columbia and Collaboration for Outcomes Research and Evaluation, Vancouver, and Arthritis Research CanadaRichmondBritish ColumbiaCanada
| |
Collapse
|
2
|
Naddei R, Alfani R, Bove M, Discepolo V, Mozzillo F, Guarino A, Alessio M. Increased Relapse Rate During COVID-19 Lockdown in an Italian Cohort of Children With Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken) 2022; 75:326-331. [PMID: 34397168 PMCID: PMC8426691 DOI: 10.1002/acr.24768] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Revised: 07/25/2021] [Accepted: 08/10/2021] [Indexed: 11/09/2022]
Abstract
OBJECTIVE Changes of routine disease management associated with COVID-19 lockdown might have potentially affected the clinical course of juvenile idiopathic arthritis (JIA). The aim of our study was to assess the rate of disease flare before and during COVID-19 lockdown to investigate its impact on disease course in children with JIA. METHODS A single-center retrospective study was conducted, including patients presenting with inactive JIA between September 1, 2018 and March 9, 2019 (group A) and between September 1, 2019 and March 9, 2020 (group B). For each patient, demographic and clinical data were collected. The rate of JIA flare from March 10, 2019 to June 30, 2019 for group A and from March 10, 2020 to June 30, 2020 for group B was compared. RESULTS Group A included 126 patients, and group B 124 patients. Statistical analysis did not show significant differences among the 2 cohorts with respect to age, sex, age at JIA onset, JIA subtype, co-occurrence of uveitis, antinuclear antibody positivity, and past or ongoing medications. The rate of disease flare during lockdown at the time of the first COVID-19 pandemic wave was significantly higher in comparison to the previous year (16.9% versus 6.3%; P = 0.009). CONCLUSION Our study showed that COVID-19 lockdown was associated with a higher rate of joint inflammation in children with JIA. This finding has a considerable clinical implication, as restrictive measures may be necessary in order to contain pandemics. Our data highlight the need for rearrangement in the home and health care management of children with JIA during lockdowns.
Collapse
|
3
|
Fouad AM, Elotla SF, Elkaraly NE, Mohamed AE. Impact of COVID-19 Pandemic on Patients with Rheumatic and Musculoskeletal Diseases: Disruptions in Care and Self-Reported Outcomes. J Patient Exp 2022; 9:23743735221102678. [PMID: 35647269 PMCID: PMC9134452 DOI: 10.1177/23743735221102678] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The COVID-19 pandemic presented a challenge to the care of patients with
rheumatic and musculoskeletal diseases (RMDs). The objective of this study was
to evaluate the impact of the pandemic on the care of RMDs patients and their
health and well-being. This cross-sectional study involved 120 RMDs patients at
the rheumatology department at Suez Canal University Hospital in Ismailia,
Egypt, in July 2020. Patients were interviewed for sociodemographic and
disease-related history. Further assessments were performed using Kessler
6-items, fears of COVID-19, and COV19–impact on quality of life scales.
Rheumatoid arthritis and systemic lupus erythematosus represented the majority
of our sample of RMDs patients (72.5% and 19.2%, respectively). About 50% of
patients reported experiencing limitations in the access to rheumatologic care,
and a similar percentage had changed or discontinued their medications.
Disease-modifying antirheumatic drugs shortage and concerns about the increased
risk of COVID-19 infection due to immunosuppressive drugs were the most
frequently reported reasons for nonadherence. The percentage of patients with
uncontrolled disease had significantly increased from 8.3% prior to the COVID-19
pandemic to 20% during the pandemic. About 60% of patients reported a high level
of psychological distress. In conclusion, the pandemic negatively influenced
mental health, quality of life, adherence to medications, access to rheumatology
care, and the degree of disease control of RMDs patients.
Collapse
Affiliation(s)
- Ahmed M Fouad
- Department of Public Health, Occupational and Environmental Medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
| | - Sally F Elotla
- Department of Public Health, Occupational and Environmental Medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
| | - Nourhan E Elkaraly
- Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
| | - Aly E Mohamed
- Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
| |
Collapse
|
4
|
Wang F, Ma Y, Xu S, Liu H, Chen Y, Yang H, Shao M, Xu W, Kong J, Chen L, Xu S, Shuai Z, Pan F. Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis. Clin Rheumatol 2022; 41:2213-2223. [PMID: 35352217 PMCID: PMC8964246 DOI: 10.1007/s10067-022-06087-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 01/03/2022] [Accepted: 01/29/2022] [Indexed: 02/06/2023]
Abstract
Objectives COVID-19 pandemic has already had a tremendous impact on the process of human society; the survival of mankind and the healthy living environment deterioration with the influence will last for many years. This meta-analysis aims to assess the risk of COVID-19 in patients with rheumatic diseases. Methods PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Chinese Biomedical Database (CBM) were systematically searched with no language restriction up to July 5, 2021. The pooled rates were synthesized by fixed effect model or random effect model depending on heterogeneity. Results A total of 83 articles were included in this meta-analysis. The incidence of COVID-19 in patient with rheumatic diseases was 0.0190 (95% CI: 0.0136-0.0252), and the hospitalization rate, intensive care unit admission rate, mechanical ventilation rate, and case fatality rate of patients with rheumatic diseases infected with COVID-19 were 0.4396 (95% CI: 0.3899-0.4898), 0.0635 (95% CI: 0.0453-0.0836), 0.0461 (95% CI: 0.0330-0.0609), and 0.0346 (95% CI: 0.0218-0.0493), respectively. Conclusions Our research shows that patients with rheumatic diseases have great risk of COVID-19. Differences in COVID-19 incidence, hospitalization rates, and mortality rates in regions were statistically significant. We still need to pay attention to the risk of COVID-19 in patients with rheumatic diseases. Key Points • Although the risk of COVID-19 in patients with rheumatic diseases has been discussed in previous meta-analysis, their research directions were inconsistent, and few studies focus on prevalence or serious outcomes of COVID-19 in patient with rheumatic diseases, while the quality of these articles was variable. • The incidence of COVID-19 and serious clinical outcomes in patients with rheumatic diseases were still high along with differential risks in most regions. • The use of glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs did not affect the hospitalization rate and mortality in rheumatism patients with COVID-19. Supplementary Information The online version contains supplementary material available at 10.1007/s10067-022-06087-1.
Collapse
Affiliation(s)
- Feier Wang
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China.,The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China
| | - Yubo Ma
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China.,The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China
| | - Shanshan Xu
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China.,The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China
| | - Huanhuan Liu
- Department of Clinical Laboratory, the Second Hospital of Anhui Medical University, 678 Furong Road, Hefei, Anhui, China
| | - Yuting Chen
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China.,The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China
| | - Hui Yang
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China.,The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China
| | - Ming Shao
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China.,The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China
| | - Wei Xu
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China.,The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China
| | - Jiangping Kong
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China.,The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China
| | - Liwen Chen
- Department of Clinical Laboratory, the Second Hospital of Anhui Medical University, 678 Furong Road, Hefei, Anhui, China
| | - Shengqian Xu
- Department of Rheumatism and Immunity, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China
| | - Zongwen Shuai
- Department of Rheumatism and Immunity, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China
| | - Faming Pan
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. .,The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China.
| |
Collapse
|
5
|
Benavent D, Garrido-Cumbrera M, Plasencia-Rodríguez C, Marzo-Ortega H, Christen L, Correa-Fernández J, Plazuelo-Ramos P, Webb D, Navarro-Compán V. Poor health and functioning in patients with axial spondyloarthritis during the COVID-19 pandemic and lockdown: REUMAVID study (phase 1). Ther Adv Musculoskelet Dis 2022; 14:1759720X211066685. [PMID: 35069810 PMCID: PMC8777346 DOI: 10.1177/1759720x211066685] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Accepted: 11/15/2021] [Indexed: 12/24/2022] Open
Abstract
Aim: To evaluate the overall health and functioning in patients with axial
spondyloarthritis (axSpA) and related factors affecting these during the
COVID-19 pandemic and lockdown measures. Methods: Data from 587 axSpA patients participating in the first phase (April–July
2020) of the REUMAVID study who completed the ASAS Health Index (ASAS-HI)
were analysed. REUMAVID is a cross-sectional study that collects data
through an online survey to assess the impact of the COVID-19 pandemic on
patients with rheumatic and musculoskeletal diseases across seven European
countries. Poor health was defined as ASAS-HI ⩾ 12. The World Health
Organization Five well-being index, self-perceived health status and change
in health status during COVID-19 pandemic were evaluated as secondary
outcomes. Logistic regression models were used to identify the factors
associated with poor health. Results: According to the ASAS-HI, 147 (25.0%) patients reported poor health. Pain and
moving around were the main affected categories. In addition, 14.0% reported
their self-perceived health status as ‘bad’ or ‘very bad’ and 46.8% as worse
than before the pandemic. In the multivariate analysis, smoking (OR = 1.98),
diabetes (OR = 4.89) and taking painkillers (OR = 2.82) or corticosteroids
use (OR = 2.20) were significantly associated with poor health, while
engaging in physical activity (OR = 0.54) and being actively employed
(OR = 0.48) were inversely associated with this. Conclusions: During the first wave of the COVID-19 pandemic, one in four axSpA patients
reported poor health and functioning, while the self-perceived health status
of almost half of these patients worsened. Nonsmoking, physical activity and
being employed were associated with better outcomes.
Collapse
Affiliation(s)
- Diego Benavent
- Rheumatology Service, IdiPAZ, La Paz University Hospital, Paseo de la Castellana, 261, Madrid 28046, Spain
| | | | | | - Helena Marzo-Ortega
- NIHR Leeds Biomedical Research Centre, LTHT and LIRMM, University of Leeds, Leeds, UK
| | | | | | | | | | | |
Collapse
|
6
|
Sabetkish N, Rahmani A. The overall impact of COVID-19 on healthcare during the pandemic: A multidisciplinary point of view. Health Sci Rep 2021; 4:e386. [PMID: 34622020 PMCID: PMC8485600 DOI: 10.1002/hsr2.386] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 08/21/2021] [Accepted: 08/22/2021] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND AND AIMS The Coronavirus disease 2019 (COVID-19) pandemic globally changed the priorities of medical and surgical procedures. It has caused many healthcare systems to stop performing their routine screenings. Altering medical clinics to COVID-19 referral centers, lockdowns, and the public fear to refer to medical centers caused a significant reduction in the referral rate; especially in the elderly. This short review article highlights the transform in clinical practice during the post-COVID era and the need for future medical revolutions. METHODS A comprehensive literature search was separately performed by both authors. The articles published between 2019 and August 2021 were included in this study and selected according to a quality appraisal method. RESULTS We have summarized the possible corresponding changes in the diagnosis and treatment of all fields of medical care including internal medicine, surgical, and minor subcategories after the COVID-19 pandemic. We have also discussed the potential impacts of the pandemic on all these different categories and subcategories of medicine, including the outpatient setting and clinical work. We do believe that the lack of routine check-ups has led to an increase in the stage of disease in patients with a previously diagnosed problem. On the other hand, the dramatic change in the lifestyle of the population including restricted mobility and increased consumption of unhealthy food has caused metabolic syndrome and other new diseases that have not been diagnosed and properly managed. CONCLUSION Our findings revealed the urgent need for public health awareness. It indicated the need to carry out both psychological and screening approaches in the post-COVID era to not miss patients with a chronic disease and new cases who were undiagnosed during the COVID pandemic.
Collapse
Affiliation(s)
- Nastaran Sabetkish
- Pediatric Urology and Regenerative Medicine Research Center, Section of Tissue Engineering and Stem Cells Therapy, Children's Hospital Medical CenterTehran University of Medical SciencesTehranIran
- ImmunologyAsthma and Allergy Research Institute, Tehran University of Medical SciencesTehranIran
| | - Alireza Rahmani
- Research Center for Prevention of Cardiovascular DiseaseInstitute of Endocrinology & Metabolism, Iran University of Medical SciencesTehranIran
| |
Collapse
|
7
|
Carbone T, Picerno V, Pafundi V, Esposito E, Leccese P, Padula AA, D'Angelo S. Impact of the COVID-19 Pandemic on the Appropriateness of Diagnostic Pathways of Autoimmune Rheumatic Diseases. J Rheumatol 2021; 49:219-224. [PMID: 34654735 DOI: 10.3899/jrheum.210611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/30/2021] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Early diagnosis of autoimmune rheumatic diseases (ARDs) is key to achieving effective treatment and improving prognosis. The coronavirus disease 2019 (COVID-19) pandemic has led to major changes in clinical practice on a global scale. We aimed to evaluate the impact of the COVID-19 pandemic on rheumatological clinical practice and autoimmunity testing demands. METHODS Data regarding the first rheumatological visits and new diagnoses, together with the autoimmunity laboratory testing volumes related to the COVID-19 pandemic phase (January-December 2020), were collected from medical records and the laboratory information system of a regional reference hospital (Basilicata, Italy) and compared with those obtained during the corresponding period in 2019. RESULTS A significant decrease in the 2020 autoimmunity laboratory test volume was found when compared with the same period in 2019 (9912 vs 14,100; P < 0.05). A significant decrease in first rheumatological visits and diagnosis (1272 vs 2336; P < 0.05) was also observed. However, an equivalent or higher percentage of positive autoimmunity results from outpatient services was recorded during 2020 when compared to the prepandemic state. Of note, COVID-19-associated decline in new diagnoses affected mainly less severe diseases. In contrast, ARDs with systemic involvement were diagnosed at the same levels as in the prepandemic period. CONCLUSION The COVID-19 pandemic has affected access to health services. However, our study highlighted that during the outbreak, greater appropriateness of the requests for laboratory tests and visits emerged, as shown by a greater percentage of positive test results and new diagnoses of more severe ARDs compared to the prepandemic period.
Collapse
Affiliation(s)
- Teresa Carbone
- T. Carbone, PhD, Laboratory of Clinical Pathology, Azienda Sanitaria di Matera (ASM), Matera; V. Picerno, MD, P. Leccese, MD, A.A. Padula, MD, S. D'Angelo, MD, PhD, Rheumatology Institute of Lucania - San Carlo Hospital, Potenza; V. Pafundi, MD, Immunopathology Laboratory, San Carlo Hospital, Potenza; E. Esposito, MD, Health Department, Basilicata Region, Potenza, Italy. T. Carbone and V. Picerno contributed equally. The authors declare no conflict of interests relevant to this article. Address correspondence to Dr. V. Pafundi, Immunopathology Laboratory, San Carlo Hospital, Potito Petrone St., 85100 Potenza, Italy. . Accepted for publication September 30, 2021
| | - Valentina Picerno
- T. Carbone, PhD, Laboratory of Clinical Pathology, Azienda Sanitaria di Matera (ASM), Matera; V. Picerno, MD, P. Leccese, MD, A.A. Padula, MD, S. D'Angelo, MD, PhD, Rheumatology Institute of Lucania - San Carlo Hospital, Potenza; V. Pafundi, MD, Immunopathology Laboratory, San Carlo Hospital, Potenza; E. Esposito, MD, Health Department, Basilicata Region, Potenza, Italy. T. Carbone and V. Picerno contributed equally. The authors declare no conflict of interests relevant to this article. Address correspondence to Dr. V. Pafundi, Immunopathology Laboratory, San Carlo Hospital, Potito Petrone St., 85100 Potenza, Italy. . Accepted for publication September 30, 2021
| | - Vito Pafundi
- T. Carbone, PhD, Laboratory of Clinical Pathology, Azienda Sanitaria di Matera (ASM), Matera; V. Picerno, MD, P. Leccese, MD, A.A. Padula, MD, S. D'Angelo, MD, PhD, Rheumatology Institute of Lucania - San Carlo Hospital, Potenza; V. Pafundi, MD, Immunopathology Laboratory, San Carlo Hospital, Potenza; E. Esposito, MD, Health Department, Basilicata Region, Potenza, Italy. T. Carbone and V. Picerno contributed equally. The authors declare no conflict of interests relevant to this article. Address correspondence to Dr. V. Pafundi, Immunopathology Laboratory, San Carlo Hospital, Potito Petrone St., 85100 Potenza, Italy. . Accepted for publication September 30, 2021
| | - Ernesto Esposito
- T. Carbone, PhD, Laboratory of Clinical Pathology, Azienda Sanitaria di Matera (ASM), Matera; V. Picerno, MD, P. Leccese, MD, A.A. Padula, MD, S. D'Angelo, MD, PhD, Rheumatology Institute of Lucania - San Carlo Hospital, Potenza; V. Pafundi, MD, Immunopathology Laboratory, San Carlo Hospital, Potenza; E. Esposito, MD, Health Department, Basilicata Region, Potenza, Italy. T. Carbone and V. Picerno contributed equally. The authors declare no conflict of interests relevant to this article. Address correspondence to Dr. V. Pafundi, Immunopathology Laboratory, San Carlo Hospital, Potito Petrone St., 85100 Potenza, Italy. . Accepted for publication September 30, 2021
| | - Pietro Leccese
- T. Carbone, PhD, Laboratory of Clinical Pathology, Azienda Sanitaria di Matera (ASM), Matera; V. Picerno, MD, P. Leccese, MD, A.A. Padula, MD, S. D'Angelo, MD, PhD, Rheumatology Institute of Lucania - San Carlo Hospital, Potenza; V. Pafundi, MD, Immunopathology Laboratory, San Carlo Hospital, Potenza; E. Esposito, MD, Health Department, Basilicata Region, Potenza, Italy. T. Carbone and V. Picerno contributed equally. The authors declare no conflict of interests relevant to this article. Address correspondence to Dr. V. Pafundi, Immunopathology Laboratory, San Carlo Hospital, Potito Petrone St., 85100 Potenza, Italy. . Accepted for publication September 30, 2021
| | - Angela Anna Padula
- T. Carbone, PhD, Laboratory of Clinical Pathology, Azienda Sanitaria di Matera (ASM), Matera; V. Picerno, MD, P. Leccese, MD, A.A. Padula, MD, S. D'Angelo, MD, PhD, Rheumatology Institute of Lucania - San Carlo Hospital, Potenza; V. Pafundi, MD, Immunopathology Laboratory, San Carlo Hospital, Potenza; E. Esposito, MD, Health Department, Basilicata Region, Potenza, Italy. T. Carbone and V. Picerno contributed equally. The authors declare no conflict of interests relevant to this article. Address correspondence to Dr. V. Pafundi, Immunopathology Laboratory, San Carlo Hospital, Potito Petrone St., 85100 Potenza, Italy. . Accepted for publication September 30, 2021
| | - Salvatore D'Angelo
- T. Carbone, PhD, Laboratory of Clinical Pathology, Azienda Sanitaria di Matera (ASM), Matera; V. Picerno, MD, P. Leccese, MD, A.A. Padula, MD, S. D'Angelo, MD, PhD, Rheumatology Institute of Lucania - San Carlo Hospital, Potenza; V. Pafundi, MD, Immunopathology Laboratory, San Carlo Hospital, Potenza; E. Esposito, MD, Health Department, Basilicata Region, Potenza, Italy. T. Carbone and V. Picerno contributed equally. The authors declare no conflict of interests relevant to this article. Address correspondence to Dr. V. Pafundi, Immunopathology Laboratory, San Carlo Hospital, Potito Petrone St., 85100 Potenza, Italy. . Accepted for publication September 30, 2021
| |
Collapse
|
8
|
Wendling D, Verhoeven F, Chouk M, Prati C. Le SARS-CoV-2 peut-il induire une arthrite réactionnelle ? REVUE DU RHUMATISME 2021; 88:326-328. [PMID: 33824573 PMCID: PMC8017909 DOI: 10.1016/j.rhum.2021.03.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Accepted: 10/07/2020] [Indexed: 11/19/2022]
Affiliation(s)
- Daniel Wendling
- Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France
- EA 4266, Pathogens and inflammation, EPILAB, université Bourgogne Franche-Comté, Besançon, France
| | - Frank Verhoeven
- Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France
- EA 4267, PEPITE, université Bourgogne Franche-Comté, Besançon, France
| | - Mickael Chouk
- Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France
| | - Clément Prati
- Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France
- EA 4267, PEPITE, université Bourgogne Franche-Comté, Besançon, France
| |
Collapse
|
9
|
Harrison SR, Garrido-Cumbrera M, Navarro-Compán V, Correa-Fernández J, Webb D, Christen L, Marzo-Ortega H. Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1). Rheumatol Adv Pract 2021; 5:rkab098. [PMID: 34988357 PMCID: PMC8690324 DOI: 10.1093/rap/rkab098] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Accepted: 11/17/2021] [Indexed: 01/20/2023] Open
Abstract
Objectives The aim was to compare the impact of the first wave of the coronavirus disease 2019 (COVID-19) pandemic and lockdown measures on patients with rheumatic and musculoskeletal diseases (RMDs) in the UK and other European countries (OEC). Methods REUMAVID was an online cross-sectional survey of seven European countries. The data collected included the following: demographics, lifestyle, employment, access to health-care services, disease-specific characteristics, the World Health Organization five well-being index (WHO-5), hospital anxiety and depression scale (HADS), visual analogue scale (VAS) disease activity, and the perceived acceptable symptom scale. Results One thousand eight hundred responses were received between April and July 2020 [UK, n = 558 (31.0%); OEC, n = 1242 (69.0%)]. UK patients were more likely to be older [mean (S.d.): UK 58.5 (13.4) years; OEC 50.0 (12.2) years], university educated [UK n = 302 (54.1%); OEC n = 572 (46.1%), quit smoking [UK n = 92 (59.4%); OEC n = 65 (16.2%)] and continue exercise [UK, n = 216 (49.2%); OEC, n = 228 (33.1%)], although, conversely, alcohol consumption increased [UK n = 99 (36.3%); OEC n = 98 (12.1%)]. UK patients felt informed about COVID-19 (UK 72.7%, OEC 57.4%) and kept their planned rheumatology [UK n = 87 (51.2%); OEC n = 213 (38.6%)] and/or general practice appointments [UK n = 87 (76.3%); OEC n = 310 (53.9%)]. Almost half the patients with RMDs reported a decline in health and well-being, although this was less common in UK patients [UK n = 214 (38.4%), OEC n = 618 (50.2%)], who reported better perceived acceptable symptom scale, VAS pain and HADS scores, but worse WHO-5 scores. Conclusions UK RMD patients performed better in the physical and mental health domains tested, possibly owing to a less restrictive lockdown and better health-care access. These findings have implications for health-care services globally in planning patient care after the COVID-19 pandemic.
Collapse
Affiliation(s)
- Stephanie Rose Harrison
- National Institute of Health Research (NIHR) Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust
- Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK
| | - Marco Garrido-Cumbrera
- Health and Territory Research, Universidad de Sevilla, Seville, Spain
- Axial Spondyloarthritis International Federation (ASIF), London, UK
| | | | | | - Dale Webb
- National Ankylosing Spondylitis Society (NASS), London, UK
| | - Laura Christen
- Patient Engagement, Novartis Pharma AG, Basel, Switzerland
| | - Helena Marzo-Ortega
- National Institute of Health Research (NIHR) Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust
- Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK
| |
Collapse
|
10
|
Cantero C, Pasquina P, Dao MD, Cedraschi C, Adler D, Plojoux J, Janssens JP. Impact of Confinement in Patients under Long-Term Noninvasive Ventilation during the First Wave of the SARS-CoV-2 Pandemic: A Remarkable Resilience. Respiration 2021; 100:909-917. [PMID: 34130277 PMCID: PMC8339039 DOI: 10.1159/000516327] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2020] [Accepted: 03/22/2021] [Indexed: 01/13/2023] Open
Abstract
Background During the first wave of the SARS-CoV-2 pandemic in Switzerland, confinement was imposed to limit transmission and protect vulnerable persons. These measures may have had a negative impact on perceived quality of care and symptoms in patients with chronic disorders. Objectives To determine whether patients under long-term home noninvasive ventilation (LTHNIV) for chronic respiratory failure (CRF) were negatively affected by the 56-day confinement (March–April 2020). Methods A questionnaire-based survey exploring mood disturbances (HAD), symptom scores related to NIV (S<sup>3</sup>-NIV), and perception of health-care providers during confinement was sent to all patients under LTHNIV followed up by our center. Symptom scores and data obtained by ventilator software were compared between confinement and the 56 days prior to confinement. Results Of a total of 100 eligible patients, 66 were included (median age: 66 years [IQR: 53–74]): 35 (53%) with restrictive lung disorders, 20 (30%) with OHS or SRBD, and 11 (17%) with COPD or overlap syndrome. Prevalence of anxiety (n = 7; 11%) and depressive (n = 2; 3%) disorders was remarkably low. Symptom scores were slightly higher during confinement although this difference was not clinically relevant. Technical data regarding ventilation, including compliance, did not change. Patients complained of isolation and lack of social contact. They felt supported by their relatives and caregivers but complained of the lack of regular contact and information by health-care professionals. Conclusions Patients under LTHNIV for CRF showed a remarkable resilience during the SARS-CoV-2 confinement period. Comments provided may be helpful for managing similar future health-care crises.
Collapse
Affiliation(s)
- Chloé Cantero
- Division of Pulmonary Diseases, Geneva University Hospitals, Geneva, Switzerland
| | - Patrick Pasquina
- Division of Pulmonary Diseases, Geneva University Hospitals, Geneva, Switzerland
| | - Melissa Dominicé Dao
- Division of Community Medicine, Primary Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland
| | - Christine Cedraschi
- Division of General Medical Rehabilitation and Multidisciplinary Pain Center, Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland
| | - Dan Adler
- Division of Pulmonary Diseases, Geneva University Hospitals, Geneva, Switzerland
| | - Jérôme Plojoux
- Division of Pulmonary Diseases, Geneva University Hospitals, Geneva, Switzerland
| | - Jean-Paul Janssens
- Division of Pulmonary Diseases, Geneva University Hospitals, Geneva, Switzerland
| |
Collapse
|
11
|
Ciurea A, Papagiannoulis E, Bürki K, von Loga I, Micheroli R, Möller B, Rubbert-Roth A, Andor M, Bräm R, Müller A, Dan D, Kyburz D, Distler O, Scherer A, Finckh A. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 2021; 80:238-241. [PMID: 32963052 PMCID: PMC7509948 DOI: 10.1136/annrheumdis-2020-218705] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Revised: 09/14/2020] [Accepted: 09/15/2020] [Indexed: 12/13/2022]
Abstract
OBJECTIVES To investigate whether the transient reduction in rheumatology services imposed by virus containment measures during the COVID-19 pandemic was associated with disease worsening in axial spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic arthritis (PsA). METHODS Patient-reported disease activity assessed during face-to-face visits and/or via a smartphone application were compared between three periods of each 2 months duration (before, during and after the COVID-19-wave) from January to June 2020 in 666 patients with axSpA, RA and PsA in the Swiss Clinical Quality Management cohort. RESULTS The number of consultations dropped by 52%, whereas the number of remote assessments increased by 129%. The proportion of patients with drug non-compliance slightly increased during the pandemic, the difference reaching statistical significance in axSpA (19.9% vs 13.2% before the pandemic, p=0.003). The proportion of patients with disease flares remained stable (<15%). There was no increase in mean values of the Bath Ankylosing Disease Activity Index, the Rheumatoid Arthritis Disease Activity Index-5 and the Patient Global Assessment in patients with axSpA, RA and PsA, respectively. CONCLUSION A short interruption of in-person patient-rheumatologist interactions had no major detrimental impact on the disease course of axSpA, RA and PsA as assessed by patient-reported outcomes.
Collapse
Affiliation(s)
- Adrian Ciurea
- Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | | | - Kristina Bürki
- Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | | | - Raphael Micheroli
- Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | - Burkhard Möller
- Department of Rheumatology, Clinical Immunology and Allergy, Inselspital University Hospital Bern, Bern, Switzerland
| | - Andrea Rubbert-Roth
- Division of Rheumatology, Kantonsspital Sankt Gallen, Sankt Gallen, Switzerland
| | | | - René Bräm
- Swiss Ankylosing Spondylitis Association, Zurich, Switzerland
| | | | - Diana Dan
- Department of Rheumatology, CHUV, Lausanne, Switzerland
| | - Diego Kyburz
- Department of Rheumatology, University Hospital Basel, Basel, Switzerland
| | - Oliver Distler
- Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
| | | | - Axel Finckh
- Department of Rheumatology, Geneva University Hospitals, Geneve, Switzerland
| |
Collapse
|
12
|
Wendling D, Verhoeven F, Chouk M, Prati C. Can SARS-CoV-2 trigger reactive arthritis? Joint Bone Spine 2020; 88:105086. [PMID: 33127461 PMCID: PMC7590820 DOI: 10.1016/j.jbspin.2020.105086] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Accepted: 10/07/2020] [Indexed: 12/14/2022]
Affiliation(s)
- Daniel Wendling
- Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France; EA 4266, Pathogens and inflammation, EPILAB, université Bourgogne Franche-Comté, Besançon, France.
| | - Frank Verhoeven
- Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France; EA 4267, PEPITE, université Bourgogne Franche-Comté, Besançon, France
| | - Mickael Chouk
- Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France
| | - Clément Prati
- Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France; EA 4267, PEPITE, université Bourgogne Franche-Comté, Besançon, France
| |
Collapse
|